Amphastar Pharmaceuticals Reports Net Revenues of $56.9 Million for the First Quarter Ended March 31, 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Jefferies Remains Bullish Following Amphastar Pharma's (AMPH) Strong Q1
May 14, 2015 10:27 AM EDTJefferies maintains a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH), and raised the price target to $19.00 (from $18.00), after a strong Q1. Analyst David Steinberg said that the strong Q1 was driven by a better than expected top line.
Steinberg commented on AMPH, saying, "Posting sales of $27.1M (+37% Y/Y), AMPHs base IMS injectables business contributed to half of the Q1 rev upside relative to our est, largely reflecting price... More
Amphastar Pharma (AMPH) Reports Q1 Loss of 1c/Share
May 13, 2015 6:01 AM EDTAmphastar Pharma (NASDAQ: AMPH) reported Q1 EPS of ($0.01), versus $0.00 reported last year. Revenue for the quarter came in at $56.89 million, versus $45.87 million reported last year.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
... More